NASDAQ:RCKT Rocket Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $14.45 +0.69 (+5.01%) (As of 07/1/2022 08:45 PM ET) Add Compare Share Today's Range$13.52▼$14.6850-Day Range$7.96▼$14.4552-Week Range$7.57▼$49.66Volume1.01 million shsAverage Volume653,534 shsMarket Capitalization$951.36 millionP/E RatioN/ADividend YieldN/APrice Target$64.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Rocket Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside344.6% Upside$64.25 Price TargetShort InterestBearish13.00% of Float Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.36Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.70) to ($2.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.11 out of 5 starsMedical Sector257th out of 1,412 stocksPharmaceutical Preparations Industry124th out of 673 stocks 3.5 Analyst's Opinion Consensus RatingRocket Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $64.25, Rocket Pharmaceuticals has a forecasted upside of 344.6% from its current price of $14.45.Amount of Analyst CoverageRocket Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.00% of the float of Rocket Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently decreased by 4.58%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRocket Pharmaceuticals has received a 72.94% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Rocket Pharmaceuticals is -0.81. Previous Next 1.9 News and Social Media Coverage News SentimentRocket Pharmaceuticals has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Rocket Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 17 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -73% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders36.50% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($2.70) to ($2.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Rocket Pharmaceuticals (NASDAQ:RCKT) StockRocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.Read More RCKT Stock News HeadlinesJuly 2, 2022 | msn.comRocket League announces Birthday Ball mode for 7th anniversaryJuly 2, 2022 | msn.comTurbo Golf Racing Combines the Best of Rocket League, Mario Kart, and Crazy GolfJune 30, 2022 | techcrunch.comMarketing automation startup Rocket Reach nabs $24M for expansionJune 30, 2022 | finance.yahoo.comRocket Lab Successfully Raises Orbit a Fourth Time For NASA’s CAPSTONE Moon MissionJune 29, 2022 | msn.comAge discrimination lawsuit filed against U.S. Space and Rocket CenterJune 29, 2022 | finance.yahoo.comRocket Lab’s Lunar Photon Spacecraft Successfully Completes Third Orbit Raising Maneuver for NASA’s CAPSTONE Moon MissionJune 28, 2022 | msn.comRocket Lab on a mission with NASA to launch a spacecraft into moon's orbitJune 27, 2022 | msn.com2022 Rocket Mortgage Classic features new viewing areas, youth golf zone at Detroit Golf ClubJune 27, 2022 | techcrunch.comRocket Lab’s CAPSTONE mission to the moon is key to establishing a lunar space stationJune 25, 2022 | usnews.comUkraine Already Using U.S.-Supplied Rocket Systems in Conflict - Top GeneralJune 23, 2022 | usnews.comU.S. Long-Range Rocket Systems Arrive in Ukraine - MinisterJune 23, 2022 | usnews.comU.S. Long-Range Rocket Systems Arrive in Ukraine - MinisterJune 23, 2022 | usnews.comAt Least Two Sunoil Tanks Hit in Russian Rocket Attack on MykolaivJune 22, 2022 | bbc.comThe Rhyme RocketJune 21, 2022 | usnews.comS. Korea Launches Homegrown Space Rocket in 2nd Such AttemptJune 21, 2022 | americanbankingnews.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $64.25 Average Target Price from AnalystsJune 19, 2022 | americanbankingnews.comRocket Pharmaceuticals (NASDAQ:RCKT) Trading 7.3% Higher June 18, 2022 | americanbankingnews.comRocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap Down to $10.98June 5, 2022 | msn.comMatthew Peca scores game-winning overtime goal, leads Springfield Thunderbirds past Laval Rocket in series opener (video)June 3, 2022 | cnet.comRocket Mortgage Review for June 2022June 1, 2022 | finance.yahoo.comJ.P. Morgan Sees an ‘Attractive Entry Point’ in These 2 StocksMay 20, 2022 | markets.businessinsider.comAnalyst Ratings for Rocket PharmaceuticalsMay 19, 2022 | seekingalpha.comRocket Pharma target raised to a Street high at Stifel after latest data updateMay 19, 2022 | finance.yahoo.comRocket Pharma's Gene Therapy Shows 100% Overall Survival In Immune Deficiency DisorderMay 19, 2022 | finance.yahoo.comRocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RCKT CUSIPN/A CIK1281895 Webwww.rocketpharma.com Phone(646) 440-9100Fax646-224-9585Employees151Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today7/03/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$64.25 High Stock Price Forecast$67.00 Low Stock Price Forecast$62.00 Forecasted Upside/Downside+344.6%Consensus RatingBuy Rating Score (0-4)3 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.700010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-169.07 million Net MarginsN/A Pretax MarginN/A Return on Equity-37.21% Return on Assets-33.99% Debt Debt-to-Equity Ratio0.05 Current Ratio15.68 Quick Ratio15.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.05 per share Price / Book2.05Miscellaneous Outstanding Shares65,838,000Free Float41,807,000Market Cap$951.36 million OptionableOptionable Beta1.71 Rocket Pharmaceuticals Frequently Asked Questions Should I buy or sell Rocket Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Rocket Pharmaceuticals stock. View analyst ratings for Rocket Pharmaceuticals or view top-rated stocks. What is Rocket Pharmaceuticals' stock price forecast for 2022? 5 Wall Street research analysts have issued twelve-month price targets for Rocket Pharmaceuticals' shares. Their RCKT stock forecasts range from $62.00 to $67.00. On average, they anticipate Rocket Pharmaceuticals' share price to reach $64.25 in the next year. This suggests a possible upside of 344.6% from the stock's current price. View analysts' price targets for Rocket Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Rocket Pharmaceuticals' stock performed in 2022? Rocket Pharmaceuticals' stock was trading at $21.83 on January 1st, 2022. Since then, RCKT stock has decreased by 33.8% and is now trading at $14.45. View the best growth stocks for 2022 here. When is Rocket Pharmaceuticals' next earnings date? Rocket Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Rocket Pharmaceuticals. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced its earnings results on Thursday, May, 5th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.70) by $0.03. During the same period last year, the business earned ($0.65) earnings per share. View Rocket Pharmaceuticals' earnings history. Who are Rocket Pharmaceuticals' key executives? Rocket Pharmaceuticals' management team includes the following people: Dr. Gaurav D. Shah M.D., CEO & Director (Age 47, Pay $920.2k)Ms. Kinnari Patel M.B.A., MBA, Pharm.D., PharmD, Pres & COO (Age 43, Pay $717.82k)Mr. Martin L. Wilson J.D., Gen. Counsel, Chief Compliance Officer & Sr. VP (Age 45, Pay $149.95k)Mr. Jonathan Schwartz, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 58, Pay $557.79k)Mr. John C. Militello CPA, CPA, Interim Principal Financial Officer, VP, Sr. Controller, Treasurer & Principal Accounting Officer (Age 49)Mayur Kasetty M.B.A., M.D., Bus. Devel. & Operations and Investor Relations LeadMs. Jessie Yeung M.B.A., VP of Investor Relations & Corp. Fin.Kevin Giordano, Director of Corp. CommunicationsMs. Isabel Carmona J.D., Sr. VP & Chief HR OfficerDr. Gayatri R. Rao J.D., M.D., Chief Devel. Officer of LVV & Sr. VP Who are some of Rocket Pharmaceuticals' key competitors? Some companies that are related to Rocket Pharmaceuticals include Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG), Cytokinetics (CYTK), Bausch Health Companies (BHC), Harmony Biosciences (HRMY), AbCellera Biologics (ABCL), Amicus Therapeutics (FOLD), PTC Therapeutics (PTCT), Blueprint Medicines (BPMC), Prestige Consumer Healthcare (PBH), Corcept Therapeutics (CORT) and CureVac (CVAC). View all of RCKT's competitors. What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA). What is Rocket Pharmaceuticals' stock symbol? Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT." How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Rocket Pharmaceuticals' stock price today? One share of RCKT stock can currently be purchased for approximately $14.45. How much money does Rocket Pharmaceuticals make? Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $951.36 million. The biotechnology company earns $-169.07 million in net income (profit) each year or ($2.700010) on an earnings per share basis. How many employees does Rocket Pharmaceuticals have? Rocket Pharmaceuticals employs 151 workers across the globe. How can I contact Rocket Pharmaceuticals? Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for Rocket Pharmaceuticals is www.rocketpharma.com. The biotechnology company can be reached via phone at (646) 440-9100, via email at investors@rocketpharma.com, or via fax at 646-224-9585. This page (NASDAQ:RCKT) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
